Skip to main content
. 2024 Jan 31;230(3):e637–e646. doi: 10.1093/infdis/jiae035

Figure 3.

Figure 3.

Serum neutralizing antibody GMTs and GMFR against time for the 1- and 3-dose groups against (A) RSV-A and (B) RSV-B. *In the mRNA-1345 100-µg 3-dose placebo group, lower-bound 95% CIs of 98.6, 79.2, 66.8, and 22.2 were noted at months 3, 5, 6, and 10, respectively. BL, baseline; GMFR, geometric mean fold rise; GMT, geometric mean titer; RSV, respiratory syncytial virus.